Oppenheimer Holdings, Inc. Reiterates “Buy” Rating for Omnicell, Inc. (OMCL)
Omnicell, Inc. (NASDAQ:OMCL)‘s stock had its “buy” rating reissued by equities researchers at Oppenheimer Holdings, Inc. in a research report issued to clients and investors on Thursday. They presently have a $55.00 price target on the stock. Oppenheimer Holdings, Inc.’s target price suggests a potential upside of 4.66% from the stock’s current price.
Other equities research analysts have also issued research reports about the company. Dougherty & Co increased their price target on Omnicell from $45.00 to $49.00 and gave the stock a “buy” rating in a research note on Friday, July 28th. Craig Hallum increased their price target on Omnicell from $46.00 to $52.00 and gave the stock a “buy” rating in a research note on Friday, July 28th. BidaskClub lowered Omnicell from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Cantor Fitzgerald reiterated a “buy” rating and issued a $47.00 price target on shares of Omnicell in a research note on Tuesday, July 25th. Finally, Zacks Investment Research upgraded Omnicell from a “sell” rating to a “hold” rating in a research note on Tuesday, July 4th. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $51.86.
Shares of Omnicell (NASDAQ OMCL) traded down 1.094% during trading on Thursday, hitting $51.975. The stock had a trading volume of 56,587 shares. Omnicell has a 1-year low of $30.35 and a 1-year high of $52.95. The stock’s 50-day moving average price is $50.58 and its 200 day moving average price is $45.38. The firm’s market capitalization is $1.95 billion.
Omnicell (NASDAQ:OMCL) last issued its quarterly earnings results on Thursday, July 27th. The company reported $0.02 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.02. Omnicell had a positive return on equity of 0.41% and a negative net margin of 1.14%. The business had revenue of $180.90 million during the quarter, compared to analyst estimates of $174.08 million. During the same quarter in the prior year, the business posted $0.38 EPS. Omnicell’s revenue for the quarter was up 4.6% compared to the same quarter last year. On average, analysts anticipate that Omnicell will post $1.30 earnings per share for the current year.
In other news, VP Peter J. Kuipers sold 3,532 shares of the firm’s stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $50.96, for a total transaction of $179,990.72. Following the completion of the transaction, the vice president now owns 40,714 shares in the company, valued at $2,074,785.44. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Dan S. Johnston sold 16,400 shares of the firm’s stock in a transaction dated Friday, August 18th. The shares were sold at an average price of $48.86, for a total value of $801,304.00. Following the transaction, the executive vice president now owns 51,621 shares of the company’s stock, valued at approximately $2,522,202.06. The disclosure for this sale can be found here. Insiders sold a total of 184,094 shares of company stock valued at $9,094,791 in the last quarter. 3.77% of the stock is currently owned by company insiders.
Several institutional investors have recently modified their holdings of the company. 1st Global Advisors Inc. grew its position in shares of Omnicell by 1.5% during the second quarter. 1st Global Advisors Inc. now owns 7,948 shares of the company’s stock valued at $343,000 after purchasing an additional 120 shares in the last quarter. Piedmont Investment Advisors LLC purchased a new position in shares of Omnicell during the second quarter valued at about $346,000. Westwood Holdings Group Inc. grew its position in shares of Omnicell by 27.2% during the second quarter. Westwood Holdings Group Inc. now owns 439,617 shares of the company’s stock valued at $18,948,000 after purchasing an additional 94,070 shares in the last quarter. Martin & Co. Inc. TN grew its position in shares of Omnicell by 1.7% during the second quarter. Martin & Co. Inc. TN now owns 65,990 shares of the company’s stock valued at $2,844,000 after purchasing an additional 1,100 shares in the last quarter. Finally, The Manufacturers Life Insurance Company grew its position in shares of Omnicell by 2.2% during the second quarter. The Manufacturers Life Insurance Company now owns 27,880 shares of the company’s stock valued at $1,202,000 after purchasing an additional 605 shares in the last quarter.
Omnicell Company Profile
Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.
Receive News & Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.